Hamamatsu Photonics KK

BRIDGEWATER, N.J., Oct. 3, 2024 /PRNewswire/ -- PictorLabs, a leader in AI-powered virtual staining technology, and Hamamatsu Photonics, a renowned provider of whole slide imaging systems, are excited to announce a strategic partnership to develop cutting-edge applications to advance virtual staining in routine laboratory practices. Innovations with AI and advanced imaging PictorLabs, a rapidly growing startup spun off from the UCLA Colleges of Engineering and Medicine, has been at the forefront of the digital transformation of histopathology. By leveraging AI-powered algorithms, PictorLabs eliminates the need for toxic reagents while significantly reducing turnaround times when compared to traditional chemical stain results. With PictorLabs technology and the ability to run multiple stains on a single slide, clinicians and researchers will be able to access digitally stained slides in minutes, enabling faster experiments, less tissue consumption, and better-informed insights. Hamamatsu Corporation is the North American subsidiary of Hamamatsu Photonics K.K. (Japan), a leading manufacturer of devices for the generation and measurement of infrared, visible, and ultraviolet light. Known for its NanoZoomer series of whole slide scanners, Hamamatsu has been a pivotal player in advancing digital pathology. NanoZoomer systems are renowned for their reproducibility and reliability, making them a trusted choice for laboratories worldwide. The collaboration between PictorLabs and Hamamatsu Photonics aims to explore the growing demand for efficient, scalable digital pathology solutions that can ultimately streamline the workflows and accelerate the adoption of digital pathology at an enterprise scale. Quotes "This partnership marks a significant milestone in the digital transformation of pathology," said Yair Rivenson, CEO, CTO & Co-Founder of PictorLabs. "By combining our AI-powered virtual staining technology with Hamamatsu's state-of-the-art imaging systems, we are poised to revolutionize the way laboratories approach histopathology." "As we look into the future of pathology, we aim to explore areas that not only hold potential but also showcase the innovative spirit of Hamamatsu. We are excited to explore these possibilities with Pictor Labs," said Earl Hergert, President/CEO at Hamamatsu Corporation. About Hamamatsu Corporation Hamamatsu Corporation is the North American subsidiary of Hamamatsu Photonics K.K. (Japan), a leading manufacturer of devices for the generation and measurement of infrared, visible, and ultraviolet light. These devices include photodiodes, silicon photomultipliers, photomultiplier tubes, scientific light sources, infrared detectors, image sensors, spectrometers, cameras, and whole slide imaging systems. The parent company is dedicated to the advancement of photonics through extensive research. This corporate philosophy results in state-of-the-art products which are used throughout the world in scientific, industrial, and commercial applications. For more information, visit . About Pictor Labs PictorLabs is a software company that is transforming the practice of histopathology with AI-powered virtual staining. Based in Los Angeles and spun off from the UCLA Colleges of Engineering and Medicine, PictorLabs is a venture-backed startup leading the digital transformation of histological staining. By delivering digitally stained slides in minutes, PictorLabs will enable faster results with better insights for research, pharma, and clinical applications, ultimately improving histopathology operations and outcomes. For more information about PictorLabs and its AI-powered virtual staining technology, please visit . Information furnished by Hamamatsu Corporation is believed to be reliable. However, no responsibility is assumed for possible inaccuracies or omissions. Specifications are subject to change without notice. SOURCE Hamamatsu Corporation WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

BRIDGEWATER, N.J., May 22, 2024 /PRNewswire/ -- Indica Labs, an industry leader in AI-powered digital pathology solutions, and Hamamatsu Photonics K.K., a pioneer in whole slide imaging systems, announce that the U.S. Food and Drug Administration (FDA) has issued a 510(k) clearance to Indica Labs for HALO AP Dx, an enterprise digital pathology platform. HALO AP Dx is indicated for primary diagnosis of surgical pathology slides prepared from formalin-fixed paraffin embedded (FFPE) tissue scanned by the NanoZoomer® S360MD Slide scanner1. This 510(k) clearance from the FDA expands on an established partnership between Indica Labs and Hamamatsu Photonics K.K. Steven Hashagen, founder and CEO of Indica Labs said, "This FDA clearance for primary diagnosis of surgical pathology slides prepared from FFPE tissue is a significant milestone for HALO AP Dx that builds upon our prior CE-IVDR certification for HALO AP®. We're proud that our collaboration with Hamamatsu allowed us to leverage images from their NanoZoomer Slide scanner and led directly to this landmark achievement that will provide value to patients and healthcare providers alike." HALO AP® is a case-centric digital pathology platform that is deployed worldwide and has transformed the way pathologists and researchers analyze, manage, and utilize digital pathology images through its comprehensive suite of tools and features for efficient and accurate image evaluation, management, and collaboration. HALO AP® and Hamamatsu NanoZoomer Slide scanners are already in use together at a variety of institutions and centers in the US for research purposes, and in the EU and the UK for clinical applications. In the US, Indica Labs will continue to offer HALO AP® for Research Use Only applications, and will now also offer HALO AP Dx for primary diagnosis of surgical pathology slides prepared from FFPE tissue. The NanoZoomer® S360MD Slide scanner system is an expertly crafted digital pathology solution that displays images and provides image management tools and aids qualified pathologists in the review and interpretation of digital images of surgical pathology slides prepared from FFPE tissue. Fumio Iwase, Executive Officer, Division Director, Systems Division at Hamamatsu Photonics K.K. said, "We believe that comprehensive tools are key to the advancement of digital pathology. The 510(k) clearance of the Indica Labs HALO AP Dx for review of images acquired with the previously 510(k)-cleared NanoZoomer® S360MD Slide scanner system is a testament to the unwavering quality and confidence that both partners consistently deliver to our valued customers. This regulatory achievement represents a significant stride forward, underscoring our joint commitment to providing cutting-edge solutions that elevate standards in the digital pathology field and empower professionals in their diagnostic endeavors." 1HALO AP Dx (K232833) is FDA-cleared for primary diagnostic use with the Hamamatsu NanoZoomer® S360MD Slide scanner in the US. In addition, HALO AP Dx provides built-in compliance and certifications with FDA 21 CFR Part 11 and HIPAA. HALO AP® is CE-IVDR marked for in-vitro diagnostic use in Europe, the UK, and Switzerland. HALO AP is For Research Use Only in the US and is not FDA cleared for clinical diagnostic use. In addition, HALO AP provides built-in compliance and certifications with FDA 21 CFR Part 11, HIPAA, and GDPR. About Indica Labs Indica Labs is the world's leading provider of AI-powered digital pathology software and services. Our flagship HALO® and HALO AI platform powers quantitative evaluation of digital pathology images. HALO Link facilitates research-focused image management and collaboration while HALO AP® and HALO AP Dx deliver enterprise digital pathology for primary diagnosis with regulatory clearances in multiple markets. Through a commitment to open pathology and a combination of performance, scalability, and usability, our software solutions enable pharma companies, diagnostic labs, hospitals, research organizations, and Indica's own contract Pharma Services team to advance tissue-based research, clinical trials, and diagnostics. About Hamamatsu Corporation Hamamatsu Corporation is the North American subsidiary of Hamamatsu Photonics K.K. (Japan), a leading manufacturer of devices for the generation and measurement of infrared, visible, and ultraviolet light. These devices include photodiodes, silicon photomultipliers, photomultiplier tubes, scientific light sources, infrared detectors, image sensors, spectrometers, and cameras. The parent company is dedicated to the advancement of photonics through extensive research. This corporate philosophy results in state-of-the-art products which are used throughout the world in scientific, industrial, and commercial applications. Information furnished by Hamamatsu Corporation is believed to be reliable. However, no responsibility is assumed for possible inaccuracies or omissions. Specifications are subject to change without notice.

DUBLIN, July 10, 2023 /PRNewswire/ -- The "Near Infrared Imaging Market Size, Share & Trends Analysis Report By Product (Devices, Reagents), By Application (Cancer Surgeries, Gastrointestinal Surgeries), By End-use, By Region, And Segment Forecasts, 2023-2030" report has been added to ResearchAndMarkets.com's offering. The global near infrared imaging market size is expected to reach USD 2.82 billion by 2030, registering a CAGR of 3.9% from 2023 to 2030 Growing usage of near infrared (NIR) fluorescence imaging due to the advantages, such as minimally invasiveness and high efficiency in diagnosing various conditions, is anticipated to drive the industry growth significantly during the forecast period. Moreover, growing incidences of chronic disorders, especially among the geriatric population, are fueling industry growth. Alzheimer's disease, dementia, arthritis, chronic kidney disease, cancer, Cardiovascular Diseases (CVDs), and diabetes are some of the commonly prevalent diseases that require NIR imaging for better diagnosis and further decision-making for effective treatment. For instance, according to the International Agency for Research on Cancer in 2020, there were about 19,292,789 new cancer cases globally. The same source states that the number is expected to reach 50,550,287 by 2025. Expanding applications of the NIR technique in the early diagnosis of various neurological conditions are expected to play a significant role in the overall industry development. As per the National Research University's Higher School of Economics, neurological disorders are one of the leading causes of disability and death today. They were reported as the leading cause group of Disability Adjusted Life Years, which comprised 16.8% of global deaths. Strategic initiatives, such as the introduction of technologically advanced fluorescence imaging systems, acquisitions, collaborations, and government approvals, by major companies, are expected to have a significant impact on the industry growth. For instance, in January 2021, Olympus Corp. entered into an agreement to acquire Quest Photonic Devices B.V. for EUR 50 million, to improve its surgical endoscopy capabilities. NIR is preferred as a process monitoring tool, especially in the pharmaceutical industry. Growing applications of NIR in commercial operations & research activities in biopharmaceutical companies as well as academic institutes are expected to drive the demand for advanced NIR systems in the coming years. Near Infrared Imaging Market Report Highlights The reagents product segment dominated the industry in 2022 owing to the development of novel reagents to identify various types of cancer The reagents segment is projected to expand further at the fastest CAGR retaining its leading position over the forecast years due to benefits offered by Indocyanine Green (ICG), such as real-time angiographic images during brain tumor or vascular surgery The cancer surgeries application segment is expected to grow at the fastest CAGR during the forecast period owing to the high prevalence of the disorder, especially in the emerging economies The hospitals & clinics end-use segment dominated the industry in 2022 owing to a rise in the number of admissions of cancer patients in clinics and hospitals Market Dynamics Market Driver Analysis Increasing number of global surgical procedures owing to the rising prevalence of target diseases Advantages of NIR imaging over conventional visualization methods Rising demand for minimally invasive procedures Market Restraint Analysis Prolonged approval process Industry Challenges Scarcity of trained professionals Near Infrared Imaging: Market Analysis Tools Industry Analysis - Porter's PESTEL Analysis Major Deals & Strategic Alliances Analysis Covid-19 Impact Analysis Competitive Analysis Stryker Karl Storz SE & Co. KG Carl Zeiss Meditec AG Leica Microsystems Olympus Fluoptics Hamamatsu Photonics K.K Quest Medical Imaging B.V. Mizuho Medical Co, Ltd. Shimadzu Corporation Visionsense, PerkinElmer, Inc. For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets